A large network meta-analysis found specific noninvasive brain stimulation (NIBS) modalities improved symptoms in treatment-resistant schizophrenia (TRS).
A large network meta-analysis found specific noninvasive brain stimulation (NIBS) modalities improved symptoms in treatment-resistant schizophrenia (TRS).
Processing speed remains one of the most severely impaired cognitive domains in people with schizophrenia, according to a large systematic review and meta-analysis published in JAMA Psychiatry.
Processing speed remains one of the most severely impaired cognitive domains in people with schizophrenia, according to a large systematic review and meta-analysis published in JAMA Psychiatry.
In a study published in Schizophrenia Research, investigators examined whether disease duration or antipsychotic exposure explains increases in brain age among patients with schizophrenia using MRI-based machine-learning models.
In a study published in Schizophrenia Research, investigators examined whether disease duration or antipsychotic exposure explains increases in brain age among patients with schizophrenia using MRI-based machine-learning models.
A randomized clinical trial evaluated adjunctive semaglutide’s effect on early metabolic abnormalities among individuals with schizophrenia spectrum disorders receiving second-generation antipsychotics (SGAs) such as clozapine or olanzapine.
A randomized clinical trial evaluated adjunctive semaglutide’s effect on early metabolic abnormalities among individuals with schizophrenia spectrum disorders receiving second-generation antipsychotics (SGAs) such as clozapine or olanzapine.
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
